Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

AbCellera Biologics Inc. ABCL NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • CA • USD

SharesGrow Score
63/100
3/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$20.17
+436.4%

AbCellera Biologics Inc. (ABCL) is a Biotechnology company in the Healthcare sector, currently trading at $3.76. It has a SharesGrow Score of 63/100, indicating a above average investment profile with 3 out of 7 criteria passed.

Analyst consensus target is ABCL = $20 (+436.4% upside).

Valuation: ABCL trades at a trailing Price-to-Earnings (P/E) of -6.9 (S&P 500 average ~25).

Financials: revenue is $75M, +14.7%/yr average growth. Net income is $146M (loss), growing at -64.5%/yr. Net profit margin is -194.9% (negative). Gross margin is 100% (+13.7 pp trend).

Balance sheet: total debt is $143M against $1.1B equity (Debt-to-Equity (D/E) ratio 0.13, conservative). Current ratio is 11.32 (strong liquidity). Debt-to-assets is 10.6%. Total assets: $1.4B.

Analyst outlook: 9 / 11 analysts rate ABCL as buy (82%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 48/100 (Partial), Past 25/100 (Fail), Health 100/100 (Pass), Moat 62/100 (Partial), Future 94/100 (Pass), Income 10/100 (Fail).

$20.17
▲ 436.44% Upside
Average Price Target
Based on 11 Wall Street analysts offering 12-month price targets for AbCellera Biologics Inc., the average price target is $20.17, with a high forecast of $34.00, and a low forecast of $5.00.
Highest Price Target
$34.00
Average Price Target
$20.17
Lowest Price Target
$5.00

ABCL SharesGrow Score Overview

63/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 48/100
Financials — average growth
PAST 25/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 62/100
Gross margin is + market cap
FUTURE 94/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — ABCL

✓
VALUE Pass
100/100
ABCL trades at a trailing Price-to-Earnings (P/E) of -6.9 (S&P 500 average ~25). Forward PEG -3.95 — Peter Lynch undervalued (≤1.0). Analyst consensus target is $20, implying +431.9% from the current price $4. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
~
GROWTH Partial
48/100
ABCL: +14.7%/yr revenue is, -64.5%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
✗
PAST Fail
25/100
ABCL: 1 / 4 years profitable. weak. Score = 1 / 4 × 100. ≥ 80 = Pass.
View details →
✓
HEALTH Pass
100/100
Balance sheet ABCL: Debt-to-Equity (D/E) ratio 0.13 (conservative), Current ratio is 11.32 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
62/100
ABCL: Gross margin is 100% (+13.7 pp trend), $1B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 62/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
94/100
Analyst outlook: 9 / 11 analysts rate ABCL as buy (82%). Analyst consensus target is $20 (+431.9% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
ABCL: Net profit margin is -194.9%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range1.891-6.515
Volume3.14M
Avg Volume (30D)3.61M
Market Cap$1.14B
Beta (1Y)0.85
Share Statistics
EPS (TTM)-0.49
Shares Outstanding$298.71M
IPO Date2020-12-11
Employees596
CEOCarl Hansen
Financial Highlights & Ratios
Revenue (TTM)$75.13M
Gross Profit$75.13M
EBITDA$-155.42M
Net Income$-146.41M
Operating Income$-217.1M
Total Cash$560.33M
Total Debt$143.22M
Net Debt$-11.8M
Total Assets$1.36B
Price / Earnings (P/E)-7.7
Price / Sales (P/S)15.17
Analyst Forecast
1Y Price Target$23.50
Target High$34.00
Target Low$5.00
Upside+525.0%
Rating ConsensusBuy
Analysts Covering11
Buy 82% Hold 18% Sell 0%
Price Target Summary
Company Info
CountryCA
ExchangeNASDAQ Global Select
CurrencyUSD
ISINCA00288U1066

Price Chart

Track all markets on TradingView
ABCL
AbCellera Biologics Inc. ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
1.89 52WK RANGE 6.52

People Also View

MDGL
MDGL
Madrigal Pharmaceuticals, Inc.
$524.99
-0.13%
 KRYS
KRYS
Krystal Biotech, Inc.
$270.00
+0.97%
 RETA
RETA
Reata Pharmaceuticals, Inc.
$172.36
+0.02%
 PTCT
PTCT
PTC Therapeutics, Inc.
$73.01
+3.68%
 SRPT
SRPT
Sarepta Therapeutics, Inc.
$22.15
+1.65%
 VIR
VIR
Vir Biotechnology, Inc.
$10.05
+7.95%
 IOVA
IOVA
Iovance Biotherapeutics, Inc.
$3.64
+5.20%
 CVAC
CVAC
CureVac N.V.
$4.66
+0.00%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message